Physician profile
Michael Lee
NPI 1447351622
$1,508.85
in general payments reported to CMS, 2019-2025
19 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.22 · 2023: $50.35 · 2024: $802 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $259.40 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $230.67 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $125.81 | 2023-2025 | Spravato, Xarelto |
| Exact Sciences Corporation | $115.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $113.94 | 2024-2025 | Farxiga, Airsupra |
| Pfizer INC. | $99.00 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $78.31 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.77 | 2025 | Ofev, Jardiance |
| Abbvie INC. | $70.73 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $46.01 | 2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.59 | 2024-2025 | Xifaxan, Trulance |
| Amgen INC. | $44.87 | 2024-2025 | Repatha, Otezla, Repatha |
| Dynavax Technologies Corporation | $43.85 | 2023-2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $39.09 | 2024 | |
| Abbott Laboratories | $36.27 | 2025 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $32.60 | 2023-2024 | Shingrix, Arexvy |
| Dexcom, INC. | $20.42 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $18.97 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $14.60 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.